NASDAQ:MDXG

MiMedx Group Competitors

$12.25

-0.15 (-1.21 %)

(As of 04/14/2021 12:28 PM ET)

Add

Compare

Today's Range

$12.06

Now: $12.25▼

$12.34

50-Day Range

$8.59

MA: $10.34▼

$12.72

52-Week Range

$3.30

Now: $12.25▼

$12.87

Volume5,641 shs

Average Volume569,119 shs

Market Capitalization$1.36 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.71

MiMedx Group (NASDAQ:MDXG) Vs. TNDM, NVRO, SWAV, ICUI, GKOS, and CMD

Should you be buying MDXG stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to MiMedx Group, including Tandem Diabetes Care (TNDM), Nevro (NVRO), ShockWave Medical (SWAV), ICU Medical (ICUI), Glaukos (GKOS), and Cantel Medical (CMD).

MiMedx Group vs. Tandem Diabetes Care Stock

Tandem Diabetes Care (NASDAQ:TNDM) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Profitability

This table compares Tandem Diabetes Care and MiMedx Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-11.10%	-10.98%	-5.59%
MiMedx Group	-37.28%	-404.08%	-58.81%

Volatility & Risk

Tandem Diabetes Care has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Valuation & Earnings

This table compares Tandem Diabetes Care and MiMedx Group's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$362.30 million	14.96	$-24,750,000.00	($0.22)	-394.09
MiMedx Group	$299.26 million	4.55	$-25,580,000.00	N/A	N/A

Tandem Diabetes Care has higher revenue and earnings than MiMedx Group.

Analyst Ratings

This is a breakdown of current recommendations for Tandem Diabetes Care and MiMedx Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	0	4	9	0	2.69
MiMedx Group	0	0	1	0	3.00

Tandem Diabetes Care currently has a consensus target price of $115.9231, indicating a potential upside of 33.71%. MiMedx Group has a consensus target price of $20.00, indicating a potential upside of 63.27%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Tandem Diabetes Care.

Insider & Institutional Ownership

88.6% of Tandem Diabetes Care shares are owned by institutional investors. Comparatively, 4.0% of MiMedx Group shares are owned by institutional investors. 6.0% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 19.8% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Tandem Diabetes Care beats MiMedx Group on 8 of the 13 factors compared between the two stocks.

MiMedx Group vs. Nevro Stock

Nevro (NYSE:NVRO) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Nevro and MiMedx Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nevro	0	3	11	0	2.79
MiMedx Group	0	0	1	0	3.00

Nevro presently has a consensus price target of $181.3846, suggesting a potential upside of 21.08%. MiMedx Group has a consensus price target of $20.00, suggesting a potential upside of 63.27%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Nevro.

Profitability

This table compares Nevro and MiMedx Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nevro	-24.46%	-30.25%	-14.57%
MiMedx Group	-37.28%	-404.08%	-58.81%

Risk & Volatility

Nevro has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.

Valuation and Earnings

This table compares Nevro and MiMedx Group's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nevro	$390.26 million	13.29	$-103,690,000.00	($3.37)	-44.45
MiMedx Group	$299.26 million	4.55	$-25,580,000.00	N/A	N/A

MiMedx Group has lower revenue, but higher earnings than Nevro.

Insider & Institutional Ownership

4.0% of MiMedx Group shares are owned by institutional investors. 7.6% of Nevro shares are owned by company insiders. Comparatively, 19.8% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

MiMedx Group beats Nevro on 7 of the 13 factors compared between the two stocks.

MiMedx Group vs. ShockWave Medical Stock

MiMedx Group (NASDAQ:MDXG) and ShockWave Medical (NASDAQ:SWAV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares MiMedx Group and ShockWave Medical's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$299.26 million	4.55	$-25,580,000.00	N/A	N/A
ShockWave Medical	$42.93 million	115.62	$-51,110,000.00	($2.14)	-66.57

MiMedx Group has higher revenue and earnings than ShockWave Medical.

Profitability

This table compares MiMedx Group and ShockWave Medical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiMedx Group	-37.28%	-404.08%	-58.81%
ShockWave Medical	-108.73%	-30.28%	-25.31%

Volatility & Risk

MiMedx Group has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for MiMedx Group and ShockWave Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	0	0	1	0	3.00
ShockWave Medical	0	4	2	0	2.33

MiMedx Group currently has a consensus target price of $20.00, suggesting a potential upside of 63.27%. ShockWave Medical has a consensus target price of $112.50, suggesting a potential downside of 21.02%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts clearly believe MiMedx Group is more favorable than ShockWave Medical.

Insider & Institutional Ownership

4.0% of MiMedx Group shares are owned by institutional investors. Comparatively, 88.8% of ShockWave Medical shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by insiders. Comparatively, 15.3% of ShockWave Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MiMedx Group beats ShockWave Medical on 8 of the 13 factors compared between the two stocks.

MiMedx Group vs. ICU Medical Stock

ICU Medical (NASDAQ:ICUI) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Institutional & Insider Ownership

91.5% of ICU Medical shares are held by institutional investors. Comparatively, 4.0% of MiMedx Group shares are held by institutional investors. 10.9% of ICU Medical shares are held by insiders. Comparatively, 19.8% of MiMedx Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ICU Medical and MiMedx Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ICU Medical	6.43%	9.73%	7.70%
MiMedx Group	-37.28%	-404.08%	-58.81%

Risk and Volatility

ICU Medical has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for ICU Medical and MiMedx Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICU Medical	0	0	2	0	3.00
MiMedx Group	0	0	1	0	3.00

ICU Medical currently has a consensus target price of $240.50, suggesting a potential upside of 15.69%. MiMedx Group has a consensus target price of $20.00, suggesting a potential upside of 63.27%. Given MiMedx Group's higher probable upside, analysts plainly believe MiMedx Group is more favorable than ICU Medical.

Earnings and Valuation

This table compares ICU Medical and MiMedx Group's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICU Medical	$1.27 billion	3.48	$101.04 million	$7.36	28.25
MiMedx Group	$299.26 million	4.55	$-25,580,000.00	N/A	N/A

ICU Medical has higher revenue and earnings than MiMedx Group.

Summary

ICU Medical beats MiMedx Group on 8 of the 12 factors compared between the two stocks.

MiMedx Group vs. Glaukos Stock

MiMedx Group (NASDAQ:MDXG) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for MiMedx Group and Glaukos, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	0	0	1	0	3.00
Glaukos	1	6	1	0	2.00

MiMedx Group presently has a consensus price target of $20.00, suggesting a potential upside of 63.27%. Glaukos has a consensus price target of $66.3750, suggesting a potential downside of 21.44%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Glaukos.

Institutional and Insider Ownership

4.0% of MiMedx Group shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by company insiders. Comparatively, 8.7% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

MiMedx Group has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500.

Profitability

This table compares MiMedx Group and Glaukos' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiMedx Group	-37.28%	-404.08%	-58.81%
Glaukos	-33.61%	-7.99%	-5.87%

Earnings & Valuation

This table compares MiMedx Group and Glaukos' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$299.26 million	4.55	$-25,580,000.00	N/A	N/A
Glaukos	$236.98 million	16.32	$15.42 million	($0.10)	-844.90

Glaukos has lower revenue, but higher earnings than MiMedx Group.

MiMedx Group vs. Cantel Medical Stock

MiMedx Group (NASDAQ:MDXG) and Cantel Medical (NYSE:CMD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Profitability

This table compares MiMedx Group and Cantel Medical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiMedx Group	-37.28%	-404.08%	-58.81%
Cantel Medical	3.38%	11.19%	4.10%

Analyst Recommendations

This is a summary of current ratings and recommmendations for MiMedx Group and Cantel Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	0	0	1	0	3.00
Cantel Medical	1	2	1	0	2.00

MiMedx Group currently has a consensus target price of $20.00, suggesting a potential upside of 63.27%. Cantel Medical has a consensus target price of $71.50, suggesting a potential downside of 16.19%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts plainly believe MiMedx Group is more favorable than Cantel Medical.

Insider and Institutional Ownership

4.0% of MiMedx Group shares are held by institutional investors. Comparatively, 95.0% of Cantel Medical shares are held by institutional investors. 19.8% of MiMedx Group shares are held by company insiders. Comparatively, 10.7% of Cantel Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares MiMedx Group and Cantel Medical's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$299.26 million	4.55	$-25,580,000.00	N/A	N/A
Cantel Medical	$1.02 billion	3.55	$13.71 million	$1.65	51.70

Cantel Medical has higher revenue and earnings than MiMedx Group.

Risk & Volatility

MiMedx Group has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.

Summary

Cantel Medical beats MiMedx Group on 7 of the 12 factors compared between the two stocks.